Press release
Hodgkin's Lymphoma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances by DelveInsight | Checkpoint Therapeutics, Mundipharma Research, Aurigene Discovery, Immunitas Therapeutics, AstraZeneca
"Hodgkin's Lymphoma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hodgkin's Lymphoma Market.
The Hodgkin's Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hodgkin's Lymphoma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Hodgkin's Lymphoma treatment therapies with a considerable amount of success over the years.
*
Hodgkin's Lymphoma companies working in the treatment market are Checkpoint Therapeutics, Inc., Mundipharma Research Ltd., Aurigene Discovery Technologies Ltd., Immunitas Therapeutics, AstraZeneca, Tessa Therapeutics, CStone Pharmaceuticals, Tesirine ADC Therapeutics, Angiocrine Bioscience, and others, are developing therapies for the Hodgkin's Lymphoma treatment
*
Emerging Hodgkin's Lymphoma therapies in the different phases of clinical trials are- CK-301, Tinostamustine, AUR105, IMT-009, AZD7789, CD30.CAR-T, CS1001, Camidanlumab, AB-205, and others are expected to have a significant impact on the Hodgkin's Lymphoma market in the coming years.
*
In August 2023, Chimeric Therapeutics is now in Phase I of the clinical development of CHM-0201, a treatment for B-Cell Hodgkin Lymphoma. The phase transition success rate (PTSR) indication benchmark for Hodgkin lymphoma (B-cell Hodgkin lymphoma) medications in Phase I is 72%
*
In February 2022, A Phase 3 Double-Blind, Randomised, Placebo Controlled Study to Compare AB-205 Plus Standard of Care to Placebo Plus Standard of Care in Adults With Lymphoma Receiving High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE) was started by Angiocrine Bioscience
Hodgkin's Lymphoma Overview
Hodgkin's lymphoma, also known as Hodgkin lymphoma or Hodgkin disease, is a type of cancer that originates from white blood cells called lymphocytes. It is characterized by the presence of a specific type of abnormal cell called Reed-Sternberg cells in the lymph nodes. These abnormal cells are large, multinucleated cells that are typically derived from B lymphocytes (B cells).
Get a Free Sample PDF Report to know more about Hodgkin's Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight [https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Hodgkin's Lymphoma Drugs Under Different Phases of Clinical Development Include:
*
CK-301: Checkpoint Therapeutics, Inc.
*
Tinostamustine: Mundipharma Research Limited
*
AUR105: Aurigene Discovery Technologies Limited
*
IMT-009: Immunitas Therapeutics
*
AZD7789: AstraZeneca
*
CD30.CAR-T: Tessa Therapeutics
*
CS1001: CStone Pharmaceuticals
*
Camidanlumab: Tesirine ADC Therapeutics
*
AB-205: Angiocrine Bioscience
Hodgkin's Lymphoma Route of Administration
Hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Hodgkin's Lymphoma Molecule Type
Hodgkin's Lymphoma Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Hodgkin's Lymphoma Pipeline Therapeutics Assessment
*
Hodgkin's Lymphoma Assessment by Product Type
*
Hodgkin's Lymphoma By Stage and Product Type
*
Hodgkin's Lymphoma Assessment by Route of Administration
*
Hodgkin's Lymphoma By Stage and Route of Administration
*
Hodgkin's Lymphoma Assessment by Molecule Type
*
Hodgkin's Lymphoma by Stage and Molecule Type
DelveInsight's Hodgkin's Lymphoma Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Hodgkin's Lymphoma product details are provided in the report. Download the Hodgkin's Lymphoma pipeline report to learn more about the emerging Hodgkin's Lymphoma therapies [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Hodgkin's Lymphoma Therapeutics Market include:
Key companies developing therapies for Hodgkin's Lymphoma are - Actiza Pharmaceutical Private Limited, Alkem Laboratories, Amneal Pharmaceuticals, Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Incyte Corp, LGM Pharma, Merck & Co. Inc., Seagen Inc., Teva Pharmaceutical Industries Ltd., and others.
Hodgkin's Lymphoma Pipeline Analysis:
The Hodgkin's Lymphoma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin's Lymphoma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma Treatment.
*
Hodgkin's Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin's Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hodgkin's Lymphoma drugs and therapies [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hodgkin's Lymphoma Pipeline Market Drivers
*
Increase in prevalence of Hodgkin's Lymphoma, increase in awareness about the disease are some of the important factors that are fueling the Hodgkin's Lymphoma Market.
Hodgkin's Lymphoma Pipeline Market Barriers
*
However, side effects associated with the treatment, cost associated with the treatment and other factors are creating obstacles in the Hodgkin's Lymphoma Market growth.
Scope of Hodgkin's Lymphoma Pipeline Drug Insight
*
Coverage: Global
*
Key Hodgkin's Lymphoma Companies: Checkpoint Therapeutics, Inc., Mundipharma Research Ltd., Aurigene Discovery Technologies Ltd., Immunitas Therapeutics, AstraZeneca, Tessa Therapeutics, CStone Pharmaceuticals, Tesirine ADC Therapeutics, Angiocrine Bioscience, and others
*
Key Hodgkin's Lymphoma Therapies: CK-301, Tinostamustine, AUR105, IMT-009, AZD7789, CD30.CAR-T, CS1001, Camidanlumab, AB-205, and others
*
Hodgkin's Lymphoma Therapeutic Assessment: Hodgkin's Lymphoma current marketed and Hodgkin's Lymphoma emerging therapies
*
Hodgkin's Lymphoma Market Dynamics: Hodgkin's Lymphoma market drivers and Hodgkin's Lymphoma market barriers
Request for Sample PDF Report for Hodgkin's Lymphoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Hodgkin's Lymphoma Report Introduction
2. Hodgkin's Lymphoma Executive Summary
3. Hodgkin's Lymphoma Overview
4. Hodgkin's Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Hodgkin's Lymphoma Pipeline Therapeutics
6. Hodgkin's Lymphoma Late Stage Products (Phase II/III)
7. Hodgkin's Lymphoma Mid Stage Products (Phase II)
8. Hodgkin's Lymphoma Early Stage Products (Phase I)
9. Hodgkin's Lymphoma Preclinical Stage Products
10. Hodgkin's Lymphoma Therapeutics Assessment
11. Hodgkin's Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hodgkin's Lymphoma Key Companies
14. Hodgkin's Lymphoma Key Products
15. Hodgkin's Lymphoma Unmet Needs
16 . Hodgkin's Lymphoma Market Drivers and Barriers
17. Hodgkin's Lymphoma Future Perspectives and Conclusion
18. Hodgkin's Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hodgkins-lymphoma-pipeline-dynamics-2024-fda-approvals-therapeutic-advances-by-delveinsight-checkpoint-therapeutics-mundipharma-research-aurigene-discovery-immunitas-therapeutics-astrazeneca]
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hodgkin's Lymphoma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances by DelveInsight | Checkpoint Therapeutics, Mundipharma Research, Aurigene Discovery, Immunitas Therapeutics, AstraZeneca here
News-ID: 3564499 • Views: …
More Releases from ABNewswire
Phinity Therapy Strengthens Counselling Services in Edgbaston, Sparkhill & North …
Phinity Therapy has expanded its counselling services across Edgbaston, Sparkhill, and Northfield to meet growing mental health needs in Birmingham, UK. With more residents searching for "counselling near me", the clinic now offers greater access to qualified counsellors and evidence-based therapy. Phinity Therapy continues to support local communities with compassionate, personalised care and deep knowledge of Birmingham's diverse neighbourhoods.
As Birmingham continues to evolve, so do the emotional and psychological challenges…
JCFLOW Launches New Silicone Beads and Expands Wholesale Market Reach
JCFLOW [https://jcflowbeads.com/], a leading silicone bead factory store with operations in Las Vegas and China, is excited to announce the launch of its newest range of silicone beads, designed to meet the evolving needs of DIY crafters, small businesses, and creative entrepreneurs worldwide. Alongside the product launch, JCFLOW is implementing a strategic market expansion initiative to increase accessibility, offer customization options, and strengthen its position as a global leader in…
Aspen Artist Shelly Hamill Celebrates 25 Years of Transforming Heirloom China In …
Renowned mosaic artist Shelly Hamill marks over 25 years of creating unique sculptures from recycled china, offering collectors a meaningful way to transform family heirlooms into displayable art. Trained as a Master of Mosaic in portraiture at the prestigious Orsoni studio in Venice, Italy, Hamill now expands her offerings with a new print-on-demand service and an innovative Print of the Month Club.
Shelly Hamill has spent more than a quarter century…
Earned Everyday: Military Veterans Launch Athletic Brand Teaching Youth That Con …
Husband-and-wife Veteran team Matthew and Crystal Rorebeck have transformed their military experience and parenting journey into Earned Everyday, a Weatherford/Aledo athletic apparel brand with a powerful message for young athletes. Drawing from 46 combined years of military service and raising six children through deployment cycles, the retired Majors created a brand that teaches resilience, dedication, and the value of earning success.
A new athletic apparel brand with deep roots in military…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The non hodgkin…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
